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Abstract
Ocular rosacea is an important and underdiagnosed 
chronic inflammatory disorder observed in children. 
A clinical spectrum ranging from chronic eyelid infla-
mmation, recurrent ocular redness, photophobia 
and/or hordeola/chalazions and conjunctival/corneal 
phlyctenules evolving to neovascularization and scarring 
may occur. Visual impairment and consequent amblyopia 
are frequent and corneal perforation although rare is 
the most feared complication. Ocular manifestations 
usually precede cutaneous lesions. Although few cases of 
pediatric ocular rosacea (POR) have been reported in the 
literature, many cases must have been underdiagnosed 
or misdiagnosed. The delay in diagnosis is greater than 
one year in the large majority of cases and may lead to 
serious ocular sequelae. This review aims to highlight 
the clinical features of POR, its epidemiology, easy 
diagnosis and effective treatment. We also propose new 
diagnostic criteria, in which at least three of the five 
clinical criteria must be present: (1) Chronic or recurrent 
keratoconjunctivitis and/or red eye and/or photophobia; 
(2) Chronic or recurrent blepharitis and/or chalazia/
hordeola; (3) Eyelid telangiectasia documented by an 
ophthalmologist; (4) Primary periorificial dermatitis and/
or primary features of rosacea; and (5) Positive familial 
history of cutaneous and/or ocular rosacea.
Key words: Ocular rosacea; Diagnostic criteria; Demodex 
folliculorum; Leukoma; Pediatric; Blepharoconjunctivitis; 
Chalazia
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Core tip: Ocular rosacea is a chronic inflammatory disorder 
with a clinical spectrum ranging from chronic eyelid 
inflammation, recurrent ocular redness, photophobia 
and/or hordeola/chalazions and conjunctival/corneal 
phlyctenules. Although few cases of pediatric ocular 
rosacea (POR) have been reported in the literature, many 
cases must have been underdiagnosed or misdiagnosed. 
This delay in diagnosis may lead to serious ocular 
sequelae. This review aims to highlight the clinical features 
MINIREVIEWS
109 May 2, 2016|Volume 5|Issue 2|WJD|www.wjgnet.com
Pediatric ocular rosacea, a misdiagnosed disease with high 
morbidity: Proposed diagnostic criteria
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.5314/wjd.v5.i2.109
World Journal of 
DermatologyW J D
World J Dermatol 2016 May 2; 5(2): 109-114
ISSN 2218-6190 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.
of POR, its epidemiology, new diagnostic criteria, treatment 
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INTRODUCTION
Rosacea is a chronic condition affecting the facial and 
ocular surface tissues, particularly common in the fair-
skinned population[1-4]. The American National Rosacea 
Society developed a classification system that became 
the standard one. According to the patterns of signs and 
symptoms, four major clinical subtypes of rosacea are 
described: Erythematotelangiectatic, papulopustular, 
phymatous and ocular rosacea. In children, the phy-
matous type is not seen[1-4]. These subtypes may be 
discrete variants or may be progressive from one to 
another, and they can also coexist. Ocular rosacea is one 
of the four described types of rosacea, characterized by 
involvement of eyelids, conjunctiva and corneal tissue[1-4].
The prevalence of ophthalmic involvement in rosacea 
is probably higher than previously presumed and it varies 
considerably between ophthalmic and dermatological 
studies[2,3,5]. In most adult cases, ocular manifestations are 
preceded by cutaneous signs, making the diagnosis easier. 
However, in pediatric ocular rosacea (POR) the ocular 
involvement may precede dermatologic manifestations in 
more than half of the patients[5-8], delaying the diagnosis. 
The mean delay between disease onset and the diagnosis 
is greater than one year in most case series[6,8-11], and 
greater than two years in more than half of cases[6,8-10]. 
Before the established diagnosis, many patients are seen 
by multiple ophthalmologists and/or others clinicians 
and receive various types of therapy, including topical 
antibiotics, topical corticosteroids, lubricants and antiallergic 
drops, without success[6,8,12,13]. In fact, the management 
must be multidisciplinary, including dermatologists, 
ophthalmologists and pediatricians.
The non-recognition of POR can also be a result 
of the varied names adopted in the literature and the 
lack of overall consensus: Chronic blepharokeratoc-
onjunctivitis[6,9-11,14-18], blepharokeratitis[10], chronic phly-
ctenular keratoconjunctivitis[8-10,18] phlyctenular blephar-
okeratoconjunctivitis[10,14,18], and meibomitis-related 
keratoconjunctivitis[19]. 
The main aim of this review is to make the children’s health 
care providers aware of POR, by highlighting its clinical 
features, epidemiology, easy diagnosis and treatment. 
We also propose POR criteria.
EPIDEMIOLOGIC DATA
Few cases of POR have been reported in the literature. 
In 13 published series[5-17], a total of 259 patients were 
found and the number of patients in each varied between 
3[16] and 51[15]. In another series, the largest ever 
published about POR, the sample included 615 cases, 
most of them described as mild, by Gupta et al[18] in 
2010. In others studies, the number of cases was smaller 
probably because only severe cases were reported[5-17].
POR is mostly diagnosed by ophthalmologists[6,9,11,14,15], 
making this condition rare for other physicians and is 
underdiagnosed or misdiagnosed by them[5-13,15,16]. In two 
tertiary centers of ophthalmology, in Philadelphia[10] and 
in New Deli[18], chronic blepharokeratoconjunctivitis was 
the reason for referral in 15% and 12.3% of all children, 
respectively.
In the 259 patients of the 13 series[5-17], 162 are 
girls (62.5%) and 97 are boys (37.5%), the opposite of 
what was found by Gupta et al[18] (37.5% vs 62.5%).
The median age of onset in five of the 13 series 
(122 patients) varied between 3.2 years and 7.0 years, 
with extremes of 1 mo and 17 years[6,8,9,11,17]. There is a 
significant delay in diagnosis, often more than two years, 
justifying the median age at presentation in tertiary 
centers, between 4.6 years and 10.2 years[6,7,11,18].
A positive family history for rosacea was found 
in nine of the 34 patients of two series (26.5%)[5,8]. 
However, in most series family history wasn’t reported. 
Since children with rosacea are more likely to have 
familial rosacea[1,8], it is important to obtain this clinical 
data, which can help suggesting the diagnosis.
Bamford et al[20] demonstrated that having a 
hordeolum during childhood predisposes for rosacea in 
adulthood, underlying the close relationship between 
ocular and cutaneous inflammation. Ocular rosacea may 
occur without cutaneous manifestations and in individuals 
with any subtype of rosacea, although it is noteworthy 
that 50% of patients with erythematotelagiectatic and 
papulopustular types have eye inflammation[1,5].
Fair-skinned children of European descent are more 
commonly affected, although any ethnic group can be 
afflicted[1,4,5,8,12]. 
OUR EXPERIENCE IN POR
Since July of 2009, we have diagnosed and treated eight 
cases of POR: Three males and five females. They were 
referred to our tertiary Pediatric Rheumatology and 
Ophthalmology Units due to chronic red eye of unknown 
etiology, most of them after a medical peregrination and 
multiple ineffective topical treatments.
Their median age was 10 years (3-16 years) with an 
established diagnosis two years after the first symptoms 
(0-7 years); the mean previous medical consultations 
was eight (0-30 consultations), including at least one 
evaluation for an ophthalmologist in each (maximum 
of 13 different ophthalmologists). Two children have 
evolved to leukomas (Figure 1) and a decrease in visual 
acuity (7/10 and 8/10 respectively), what are persistent 
sequelae. We have already published the first two cases 
diagnosed at our unit[21]. 
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ETIOLOGY, PATHOPHYSIOLOGY AND 
HISTOPATHOLOGY
The exact etiopathogenetic mechanism of rosacea and 
OR remains unknown. There are probably different 
regulatory systems involved[3-5,22]. The infection by 
microbial organisms may have an important role. In OR, 
Demodex folliculorum mites, a common inhabitant of 
normal human skin, possibly represents a contributing 
cofactor to the inflammatory reaction seen in both 
cutaneous and ocular disease[2-4,22,23]. 
Recently, bacterium Bacillus oleronius has been 
isolated from Demodex folliculorum mites and found to 
be responsible to trigger an immune system response. 
These seem to have a correlation with facial rosacea 
and OR[1,24].
Gastric coinfection with Helicobacter pylori has also 
been implicated, since this bacteria has the ability to 
produce flush-inducing toxins[3,4,7,22,23]. Staphylococcus 
aureus and Staphylococcus epidermidis are common 
organisms cultured from conjunctival or lid swabs, but 
their relationship with OR is questionable[7,11,12].
Recent studies focus on the role of bacterial lipases 
and interleukin-1 alpha and elevated concentrations 
of promatrix metalloproteinases in the blepharitis and 
corneal epitheliopathy, respectively[4]. Promatrix metallo-
proteinases are degrading enzymes responsible for the 
inferior corneal stromal thinning[4].
Rosacea induces vasodilation with increased blood 
flow and vessel permeability leading to erythema, 
telangiectasias and lymphedema of the affected tissues, 
especially in the eyelids[4]. The histopathological changes 
are unspecific, showing perifollicular infiltrates consisting 
of lymphohistiocytes, epithelioid and giant cells[16].
CLINICAL MANIFESTATIONS
The clinical spectrum and severity of POR is variable, 
depending on the involvement of eyelids, conjunctiva, 
cornea and other ocular findings[3,4,6]. The first manifestations 
of POR can be chronic conjunctivitis, recurrent hordeola 
and/or chronic chalazia (Figure 2)[5-8,11,16,20], which are quite 
frequent in childhood, explaining the common delay in the 
diagnosis of this condition. Nevertheless, POR is often silent, 
painless and has unspecific clinical manifestations[2-6,12,16]. 
Table 1 shows the different ocular findings in POR.
The most common manifestations are blepharitis (Figure 
3), recurrent hordeola/chalazia (Figure 2), telangiectasias 
of the lid margin (Figure 4), dry eye, conjunctivitis and 
keratitis, frequently in association (blepharoconjunctivitis, 
blepharokeratoconjunctivitis)[2-6,8,10,15]. The typical cli-
nical picture is a long history of hyperemic conjunctiva 
and intense photophobia associated with chronic ble-
pharitis, explaining why POR is frequently called bleph-
aroconjunctivitis[6,11,19].
Combining 12 series, including 245 patients, 185 
(75.5%) had bilateral involvement, generally asym-
metrical[5,6,8-17]. In the Gupta et al[18] series only 47.5% had 
bilateral involvement.
Eyelid involvement may precede the other features in 
months to years, because it is primarily an eyelid margin 
inflammation, such as blepharitis or meibomitis[4-6,8,11,13]. 
Corneal and conjunctival are secondarily involved. 
The ocular symptoms include foreign body sensation, 
pain, burning, redness, photophobia and epiphora[3-6,8,11,19]. 
As a consequence of the long diagnostic delay, more 
than a half of the children have already corneal injuries 
at diagnosis, such as punctate epithelial erosions, 
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Figure 1  Sequelae of pediatric ocular rosacea: Leukoma. 
Figure 2  Chronic conjunctivitis and chalazia in pediatric ocular rosacea.
Figure 3  Blepharitis in pediatric ocular rosacea.
Figure 4  Telangiectasias and erythema of the lid margin in pediatric 
ocular rosacea.
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subepithelial infiltrates, corneal phlyctenules, marginal 
keratitis, ulceration and corneal opacity[8,11,13]. Pediatric 
corneal involvement tends to be central or paracentral[6].
Depending on the severity, conjunctival and/or corneal 
phlyctenules may be present in 5.5%[18] up to almost 
40%[8, 11,15].
The primary features of pediatric facial rosacea are 
chronic facial flushing, non-transient erythema, papules and 
pustules (limited to the cheeks, chin and nasolabial areas), 
telangiectasias, idiopathic periorificial dermatitis and the 
ocular and periocular signs previously described[1,4,5,16]. 
Onset and severity of POR is not associated with the 
cutaneous signs[2,3,13].
DIFFERENTIAL DIAGNOSIS
As previously mentioned, symptoms of POR aren’t always 
specific and other ophthalmic disorders may present 
with similar findings, so the differential diagnosis inclu-
des a broad spectrum: Chronic conjunctivitis (viral, 
allergic, atopic), keratoconjunctivitis sicca, meibomitis, 
recurrent hordeola/chalazia, staphylococcal or seborrheic 
blepharoconjunctivitis, medication toxicity, interstitial or 
infectious (herpes simplex) keratitis, sterile or bacterial 
corneal ulcers, auto-immune diseases, sarcoidosis, 
among others (Table 2)[2-4,8,17].
PROPOSED CRITERIA FOR POR
There are no specific clinical signs neither laboratory test 
nor histopathological markers for POR[2-5,12]. Chamaillard 
et al[5] and Hong et al[16] have proposed “dermatologic 
and ophthalmologic criteria for childhood rosacea”. 
However, in these clinical criteria four of five are cutaneous 
manifestations[5,16]. Cetinkaya et al[13] have also proposed 
the “pediatric acne rosacea diagnostic criteria” as a 
combination of meibomian disease, chronic blepharitis, 
recurrent chalazia and chronic symptoms of photophobia, 
ocular irritation and redness, with or without corneal 
vascularization, that do not respond to routine medical 
treatment[13]. For Léoni et al[7], the diagnostic criteria of 
POR requires two ophthalmologic and/or two dermatologic 
criteria. 
Considering the above mentioned publications[5,7,13,16], 
in Table 3 we propose a new diagnostic criteria for POR. 
As in the previous proposed diagnostic criteria[5,16], ocular 
redness may be absent. The diagnosis of POR should be 
multidisciplinary, with the contribution of dermatologists, 
ophthalmologists and pediatricians. The presence of 
lid margin telangiectasia and erythema, together with 
meibomian gland dysfunction (chronic chalazia) and 
a long history of ocular irritation should suggest the 
diagnosis of POR[8,9,12-14], especially if there is no response 
to routine medical treatment[13].
TREATMENT
The initial therapeutic approach should always include local 
measures, such as daily warm compresses, eyelid hygiene 
with neutral baby shampoo and liquefaction and removal 
of the thick meibomian gland secretions[1-4,8,10,11,13,15]. 
Prolonged topical erythromycin ointment or, more recently, 
azithromycin 1.5% eye drops may be useful and effective 
in mild cases and in association with other treatments[14]. 
Although very few publications support their efficacy 
and its administration in children is difficult, these eye 
drops are usually used[16]. Doan et al[14] described their 
experience with topical 1.5% azithromycin eye drops 
(monotherapy) being superior to systemic erythromycin 
and considered it as a first-line therapy.
Children that prove to be intolerant to prolonged topical 
treatment or with severe ocular involvement and/or both 
severe cutaneous and ocular rosacea must be treated 
with systemic antibiotics associated to topical care[3,5-7,12,13]. 
Tetracycline and doxycycline, normally used in adults, 
are inadvisable in children younger than 7-8 years due 
to their potential bone toxicity and dental staining[1,3-6,12]. 
Alternative safe and effective options are: Erythromycin 
(30-50 mg/kg per day, three times a day), clarithromycin 
(15 mg/kg per day divided in two doses) or azithromycin 
(10-12 mg/kg per day, one dose)[1,6,10,11,13,17]. Treatment 
with oral metronidazole is another possibility, but its 
frequent neurologic adverse effects, particularly peripheral 
neuropathy, forbids prolonged therapies[4,5,7,16]. Effective 
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Table 1  Different ocular findings in pediatric ocular rosacea[1-8,10-19]
Eyelid: Telangiectasias and erythema of the lid margin, meibomian gland dysfunction, anterior blepharitis, recurrent chalazia/hordeola, madarosis 
(loss of eyelashes), trichiasis
Conjunctiva: Interpalpebral or diffuse hyperemia, papillary and/or follicular reaction, pinguecula, scarring
Cornea: Punctate erosions, pannus, superficial neovascularization, lipid deposition, spade-shaped infiltrate, scarring, thinning, ulceration, perforation, 
phlyctenula
Sclera: Episcleritis, scleritis
Insufficiency of tear film (dry eye) with abnormal Schirmer test
Uvea: Iritis (rare)
Table 2  Differential diagnosis of pediatric ocular rosacea[2-4,8,17]
Chronic conjunctivitis Medication toxicity
(viral, allergic, atopic) Interstitial keratitis
Keratoconjunctivitis sicca Infectious keratitis 
Meibomitis   (herpes simplex) 
Recurrent hordeola/chalazia Sterile or bacterial corneal ulcers
Staphylococcal blepharoconjunctivitis Auto-immune diseases 
Seborrheic blepharoconjunctivitis Sarcoidosis
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amoxicillin treatment has also been described[15]. 
In children older than eight years old the cyclines 
can be used as first systemic therapy: Minocycline, 
doxycycline[8,13,25]. After remission, prolonged treatment 
with doxycycline 40 to 100 mg once or twice daily is a 
good option[4,8,12,13,25].
The recurrence rate is high, especially within the first 
three months of treatment if systemic therapy is tapered 
too quickly[4,7,8,10,12]. Hence, therapeutic success is directly 
related to its duration, by reducing the number of 
recurrences. Prolonged treatments (over three months) 
may be required[6,8,10,13-16], with some publications 
recommending systemic antibiotic for at least six 
months[10] and others for a minimum of 12 mo[13]. Some 
patients will need oral antibiotics during several years, 
but most children may be tapered off within six months 
of treatment[6,10]. 
Intermittent treatments are necessary if shorter 
periods of systemic antibiotics are used[5,7,11]. Since 
long-term use of oral antibiotics may be problematic, 
it has been suggested that after six to twelve months 
of treatment oral therapy should be tapered slowly[4,8]. 
Some authors suggest that low maintenance dosages 
can be taken indefinitely[4], but this is questioned by 
others given its subtherapeutic dosages[16].
Topical (ocular) corticosteroids can prove useful 
for short-term exacerbations of eyelid disease and the 
management of inflammatory keratitis and episcleritis since 
they constrain eyelid and ocular inflammation[3,4,8,11-15]. 
However, its long-term use should be avoided due to their 
well-known potential side effects, such as increased intra-
ocular pressure, glaucoma and cataracts. They should 
be discontinued as soon as possible. Furthermore, their 
discontinuation can frequently lead to rosacea exacerbations 
(topical steroid dependency)[1-4,7,13-15,17]. If indicated, topical 
corticosteroids must only be used during the initial weeks 
and the drops tapered by one drop per week[7,11,13].
Cyclosporine A 0.5% to 2% eye drops (four-six 
times per day) is an interesting approach for children 
with steroid-dependent disease and in phlyctenular 
blepharokeratoconjunctivitis[14,26]. Our experience shows 
that topic cyclosporine isn’t well tolerated by children, 
probably due to the lack of a suitable preparation in 
Europe.
It was described the efficacy of ivermectin to the 
treatment of refractory cases of cutaneous ocular 
rosacea, as an antiparasitic drug effective against mites 
Demodex[27]. The treatment consist in an oral single-
dose, and despite being proscribed to children under 
five years and under 7 kg, it has been used in pediatric 
age[27]. This drug has primarily been reported in the 
treatment of immunosuppressed patients, but there are 
reports of its success in immunocompetent patients[27,28]. 
Surgical care is needed in specific cases, like corneal 
perforation[2,15,25]. Other options under investigation are 
laser and intense pulsed light therapy. Dietary intake 
of omega-3 has recently proven to be effective as an 
anti-inflammatory and in clearing meibomian gland 
secretions[2,6]. Flaxseed oil (∝-linoleic acid) 2.5 mL once 
a day for up to 12 mo, with gradual reduction to an 
alternate day administration, can be an option in children 
intolerant or non-compliant with the use of long-term 
systemic antibiotics[7].
OUTCOMES/SEQUELAE
POR can wax and wane with a recurrence rate of 40%[10]. 
Affected children suffer from chronic conjunctivitis, corneal 
pannus, corneal neovascularization, generalized keratitis 
and meibomian gland disease. Chronic symptoms and 
frequent exacerbations may lead to tissue hypertrophy, 
extensive neovascularization, scarring, corneal opacifi-
cation, corneal perforation and complications from 
secondary infections[1,4-8,11-13,15,18]. Some patients may 
develop raised intraocular pressure and cataract, possibly 
with relation to chronic topical steroid therapy[15].
The duration of the disease and the corneal invol-
vement are the determining factors of severity[4,6,13]. 
Furthermore, a prolonged therapy regimen is required to 
minimize corneal scarring and visual loss. Gradual tapering 
is recommended to avoid relapses[4,6,13]. Thus, POR can be 
a source of significant visual morbidity in children[4,6,8,15,18]. 
In comparison to adults, children seem to be more 
susceptible to corneal damage imposed by the inflam-
matory and immune response to periocular bacteria. This 
may compromise vision development, which combined 
with the position of the opacities in the cornea may be 
complicated by secondary amblyopia[1,4,6,8,10,12]. 
TAKE HOME MESSAGES
OR is a subtype of rosacea, which is a chronic inflammatory 
disease; POR is frequently under and misdiagnosed, so it 
is probably more common than we previously thought; 
POR may be associated with high morbidity, development 
of sequelae and it is a possible cause of loss of vision; 
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Table 3  Proposed diagnostic criteria of Coimbra for pediatric ocular rosacea
Chronic or recurrent1 keratoconjunctivitis and/or red eye and/or photophobia
Chronic or recurrent1 blepharitis and/or hordeola/chalazia
Eyelid telangiectasia documented by an ophthalmologist
Primary features of pediatric rosacea (facial convex areas with chronic flushing and/or erythema and/or telangiectasia, and/or papule, pustules in 
cheeks, chin, nose or central forehead and/or primary periorificial dermatitis)
Positive familial history of cutaneous and/or ocular rosacea
Diagnosis: ≥ 3 criteria; 1Chronic (≥ 2 mo); Recurrent (≥ 3 episodes lasting > 4 wk in 12 mo).
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The diagnosis is facilitated by the proposed POR criteria; 
An ophthalmologist observation is mandatory for the 
diagnosis, but it should be suggested by pediatricians or 
dermatologists; Treatment requires a minimum of three 
months’ antibiotic therapy and a subsequent gradual 
tapering.
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